cyrilzakka/clinical-trials huggingface dataset:
Early Diagnosis and Prediction of Maternal and Neonatal Diseases:

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying maternal and neonatal diseases, leveraging multimodal health data.

Maternal and neonatal health significantly impact the well-being of both mothers and infants. Early screening, diagnosis, and intervention are crucial for preventing the onset and progression of pregnancy-related diseases and neonatal conditions. In clinical practice, obstetricians and pediatricians often need to integrate a wide range of patient data, including demographic information, medical history, biochemical markers such as blood glucose and lipid levels, as well as various imaging data such as ultrasounds, fetal monitoring, and laboratory test results, to make an accurate diagnosis and develop an appropriate care plan. In an era where precision and personalized medicine are at the forefront of healthcare, the early detection and diagnosis of maternal and neonatal diseases, as well as the selection of suitable diagnostic and therapeutic strategies, have become significant challenges in clinical settings. Recent advancements in medical imaging and data analysis techniques have greatly enhanced the accuracy and effectiveness of maternal and neonatal disease diagnosis. This study aims to develop an AI-assisted decision-making system by integrating multimodal data from electronic medical records, imaging, and laboratory results, in combination with deep learning techniques. The objective is to improve diagnostic accuracy, streamline clinical workflows, and provide more personalized care options for mothers and infants. Ultimately, this system seeks to enhance health outcomes and improve the overall quality of life for both mothers and their newborns.

Eligibility Criteria:
Inclusion Criteria:

1. Pregnant women aged 18 to 45 years.
2. Women who have received prenatal care at participating centers (e.g., hospitals or clinics).
3. Availability of comprehensive electronic health records, including prenatal care data, laboratory results, and imaging records.
4. Willingness to provide consent for participation in the study and the use of historical health data for analysis.

Exclusion Criteria:

1. Women under 18 or over 45 years old.
2. Participants with insufficient follow-up data or missing critical clinical information required for predictive modeling.
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.

This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced relapse and/or metastasis following multiple prior chemotherapy treatments (\<2 lines of therapy).

Patients will receive fixed doses of selinexor tablets twice weekly in 28-day cycles. Patients may continue from one cycle to the next without interruption as along as all criteria are met and no reason for discontinuation occurs.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* confirmed SCC of the head and neck, lung, or esophagus
* 1 to 2 prior therapies
* measurable disease at screening and documented progression within the past 6 weeks

Exclusion Criteria:

* patients requiring total parenteral nutrition
* unstable cardiovascular function
* substantially impaired gastrointestinal function
* Symptomatic brain metastases
* another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.

IPX159 was developed as an extended release formulation to reduce the fluctuation in nefopam concentration compared to IR and to reduce the incidence of peak or rate related side effects.

Eligibility Criteria:
Inclusion Criteria:

1. Able to understand and willing to sign an informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization
2. Males and females aged 18-70 with a history of primary RLS for ≥6 months prior to screening
3. Symptoms of RLS by medical history on at least 15 nights during the month prior to Screening
4. BMI 18.5-32
5. Negative alcohol and drug abuse screen
6. Negative serum pregnancy test
7. Agrees to use a medically acceptable method of contraception throughout the study and for 2 months after completing the study.
8. Able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.

Exclusion Criteria:

1. Subjects who use or intend to use post screening the following medications or medication categories:

   * Sedative hypnotics, trazodone
   * Dopamine agonists, gabapentin, gabapentin enacarbil, pregabalin
   * Narcotic analgesics, other opioids, tramadol, cyclobenzaprine
   * Iron supplementation therapy
2. History of HIV, hepatitis B or C
3. Pregnant or breastfeeding.
4. History of or clinical signs of any form of epilepsy or seizures, excluding fever-related seizures in childhood.
5. History or presence of glaucoma
6. Planning to take herbal medications (eg, hypericum perforatum \[St John's Wort\], licorice, ephedra, ginkgo, ginseng) during the study.
7. Use of any investigational drug within the last 30 days or within a period of 5 times the drug's half-life, whichever is longer
8. Subjects who, in the opinion of the Investigator, should not participate in the study or are not capable of following the study schedule for any reason
9. Employees or family members of the Investigator, study site, the Sponsor, or Contract Research Organization (if any)
Trial Comparing the Safety of Two Different Intravenous Iron Formulations

The purpose of this trial is to compare the safety profile using equal doses of intravenous iron dextran versus iron sucrose. The researchers hypothesize that significantly more patients receiving intravenous iron dextran (using the current intermediate molecular weight product) will have severe adverse outcomes than patients receiving iron sucrose in the adult non-hemodialysis outpatient population. Secondly, since these severe reactions may require additional nursing time and physician interventions that may negate any cost advantage of iron dextran, the researchers hypothesize that iron sucrose will be more cost-effective than iron dextran.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 100
* To be receiving intravenous iron

Exclusion Criteria:

* Age \< 18
* Hemodialysis
* Previous exposure to intravenous iron
* Unable to provide written consent
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.


Eligibility Criteria:
Inclusion Criteria:

* Male or female ≥ 40 to ≤ 85 years of age
* History of clinically evident cardiovascular disease at high risk for a recurrent event
* Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (\> 2.6 mmol/L)
* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

* New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30%
* Uncontrolled hypertension
* Uncontrolled or recurrent ventricular tachycardia
* Untreated hyperthyroidism or hypothyroidism
* Homozygous familial hypercholesterolemia
* LDL or plasma apheresis
Evaluation of Masticatory Performance and Patient Satisfaction for Conventional and 3D Printed Implant Overdentures

The aim of this crossover clinical study was the evaluation and comparison of masticatory performance and patient satisfaction for patients rehabilitated with conventional heat cured acrylic resin and 3D printed mandibular implant overdentures retained with bar attachment.

it was concluded that 3D printed implant overdenture showed promising results regarding chewing efficiency and patient satisfaction compared to conventionally fabricated implant overdenture.

The aim of this crossover clinical study was the evaluation and comparison of masticatory performance and patient satisfaction for patients rehabilitated with conventional heat cured acrylic resin and 3D printed mandibular implant overdentures retained with bar attachment.

Materials and Methods: Twelve completely edentulous healthy participants received new conventional dentures. Four interforaminal implants were inserted in the mandible. After osseointegration, bar was constructed with trapezoidal configuration. Each patient received randomly the following overdentures using a crossover design: conventional heat cured acrylic resin overdenture, 3d printed overdenture ( developed by scanning of mandibular conventional overdenture). Masticatory performance was evaluated with the two-colour mixing ability test after 5, 10, 20, 30, and 50 masticatory cycles. Patient satisfaction was also measured using McGill Denture Satisfaction Questionnaire. Evaluation was done after 3 months of using each overdenture.

Conclusion: Within this clinical study limitations, 3D printed implant overdenture showed promising results regarding chewing efficiency and patient satisfaction compared to conventionally fabricated implant overdenture.

Eligibility Criteria:
Inclusion Criteria:

* adequate bone quantity \[classes 1-3 according to \[Lekholm and Zarb\] of the mandible in the lateral incisor and first premolar regions to receive 4 implants
* adequate restorative space \[12-15 mm from the mucosa of the mandibular ridge to the occlusal plane- Class I according to Ahuja and Cagna 23 for bar supported implant overdenture. This was verified by direct measurement of old denture
* Angel's class I maxillo-mandibular relationship.

Exclusion Criteria:

* include systemic diseases that contraindicate implant placement
* irradiation of the head and neck region
* chemotherapy within the past 3 years
* bone metabolic diseases as uncontrolled diabetes mellitus
* smoking habit
Metabolic Characteristics of Type 2 Diabetes Mellitus Combined With Acute Myocardial Infarction: A Untargeted Metabolomics Study

This study is a retrospective case-control study. In this study, through untargeted metabolomics, investigators identified several specific changed serum metabolites in T2DM patients with or without AMI and their functions/category. Moreover, researchers selected several endogenous candidate biomarkers with larger fold change for validation in expanded population to find biomarkers which effectively predict the development of STEMI in patients with T2DM.


Eligibility Criteria:
Inclusion Criteria:

* STEMI patients meet the diagnostic criteria of "Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2015)".
* STMEI patients undergoing emergency PCI should undergo emergency PCI within 12 hours of onset at Beijing Friendship Hospital affiliated to Capital Medical University.
* All diabetic patients meet the diagnostic criteria for type 2 diabetes.
* They agreed to be enrolled in the trial and signed the informed consent.

Exclusion Criteria:

* Combined with severe valvular disease or congenital heart disease, hypertension, chronic kidney disease, stroke, hyperlipidemia, previous history of coronary artery disease.
* Involved in acute infection, severe hepatic dysfunction, tumor, rheumatic immune disease.
* Incomplete clinical information.
Prevalence of May-Thurner Syndrome in 1st-degree Relatives of Symptomatic Patients

The aim is to assess the prevalence of May-Thurner syndrome in 1st-degree relatives of previously identified symptomatic patients.

May-Thurner syndrome (MTS) is a condition characterised by compression of the left common iliac vein by the right common iliac artery and the anterior spine of the 5th lumbar vertebrae. Previously thought to be a rare condition, the prevalence of MTS is thought to be underreported. MTS can lead to significant morbidity in the form of chronic venous insufficiency, venous ulceration, lower limb swelling, venous claudication, deep-vein thrombosis, varicose veins, pelvic congestion syndrome, chronic pelvic pain and chronic post-thrombotic syndrome. It is a known risk factor for development of venous incompetence and varicose veins in adolescents and young adults. Furthermore, it is known to be an a causative factor in the development of "unprovoked" DVT in younger patients, however data on the risk of development of DVT in MTS patients has to date, been unavailable.

The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To date, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent, first degree relative with symptomatic May-Thurner syndrome

Exclusion Criteria:

* Those who not give informed consent to be contacted or to be scanned.
Care for Colon 2015

The investigatior believe that implementing camera capsule endoscopy as a filter test to colonoscopy will increase screening participation, increase the number of individuals with detected intermediate- high risk adenomas or cancer, reduce the colonoscopy demand and reduce the number of complications.

The Danish national colorectal cancer screening program includes all citizens aged 50-74 years, who are invited biennially to a fecal test for invisible blood in the stool. If the test is positive the citizen is invited for a colonoscopy. 90% of the test-positive undergo colonoscopy. The detected cancers are at a significant earlier stage and survival from screening detected cancer is higher. It is also expected that cancer incidence will drop due to removal of the advanced adenomas before they develop into cancer. Although initial results are positive, there is room for improvement. Additionally there are rare but serious complications to colonoscopy in the form of bleeding or bowel perforation.

Through four years the investigators have tested the colon capsule endoscopy method, and find that the investigation is associated with significantly less discomfort and that the diagnostic ability to find polyps \> 1 cm is better than colonoscopy.

Eligibility Criteria:
Inclusion Criteria:

* Participation in the Danish colorectal screening program

Exclusion Criteria:

* None
Percutaneous Electrolysis Versus Dry Needling in Levator Scapulae

The objective will be to determine the effectiveness of ultrasound-guided percutaneous electrolysis versus ultrasound-guided dry needling in active myofascial trigger points of the levator scapulae muscle on pain intensity, disability and range of motion. A randomized clinical trial will be carried out. Fifty-four patients with at least one active myofascial trigger point in the levator scapulae muscle were recruited and divided into ultrasound-guided percutaneous electrolysis (n = 27) and ultrasound-guided dry needling (n=27). Pain intensity, disability and range of motion will measured before, immediately after and 1 week after intervention.


Eligibility Criteria:
Inclusion Criteria:

* Neck pain
* At least two active myofascial trigger point in the levator scapulae muscle

Exclusion Criteria:

* Systemic diseases
* Cognitive impairment
COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior

Effective communication is a critical component of managing pandemic outbreaks like COVID-19. This study explores COVID-19 related public knowledge, perceptions, belief in public health recommendations, intent to comply with public health recommendations, trust in information sources and preferred information sources. Participants are invited to include detailed free-text answers to make sure their COVID-19 experiences are heard.

The survey is available online in 23 languages. Free-text responses in native languages are highly encouraged. A robust global response will not only provide invaluable information to inform clinicians, healthcare institutions and governments about how to optimize the content and venue of COVID-19 messaging, but will help write a Story of COVID in the words and languages of people from all over the world.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age

Exclusion Criteria:

* Below 18 years of age
EARLY MOBILIZATION OF INTUBETED PATIENTS IN THE INTENSİVE CARE UNİT AND THE EFFECTS OF EARLY MOBILIZATION ON RESPIRATORY PATTERN AND PATIENT HEMODYNAMICS

The present study was carried out as a quasi-experimental study in order to examine the effects of early mobilization of intubated patients in the intensive care unit and the effects of early mobilization on respiratory pattern and patient hemodynamics. The sample of the study consisted of 25 intubated patients monitored in the intensive care unit at in a private hospital between May 2020 and July 2021. Ethics committee approval and study permission were obtained from the hospital before starting the data collection process. Research data, descriptive data collection form, Richmond- Agitation Sedation Scale (RASS) scale, Muscle Strength Testing (Oxford Scale) and with the mobilization of the patients 45 minute in 30-60 minute including the preparation process, (1st Stage Semi Fowler position, 2nd Stage bedside sitting position, 3rd Stage in the bedside sitting position after mobilization) were registered in the Early Mobilization Follow-up Form and collected. Number and percentage calculations, repeated measurement ANOVA and Post Hoc Sheffe, LSD test analyzes were utilized in the evaluation of the data.


Eligibility Criteria:
Inclusion Criteria:

* 18 years and over,
* Hemodiamic stability (OCD \>60, OCD \<120, respiratory rate \<35, SpO2 \>90),
* Areas of \>3/5 (Oxford scale) and above on the lower limbs with areas of secure support,
* The patient scores 0 (awake and calm) on the Richmond Agitation Sedation Scale (RASS),
* PaO2 / FiO2 ≥300,
* Body temperature below 38 degrees,
* Platelet count ≥20,000 cells / mm3,
* Having blood sugar of 60-360 mg/dl,
* Having arterial monitoring,
* Patient with 30% FiO2 due to mechanical ventilator,
* Those with mechanical ventilator-dependent ventilation method (mode) PASB,
* Patient with a PEEP value of 5 due to mechanical ventilator,
* Patient with a PASB value of 10 connected to a mechanical ventilator,
* A sample accepted by the patient who voluntarily agreed to participate in the study was approximated from the patient.

Exclusion Criteria:

* Patients under the age of 18,
* Those with hemodynamic instability (OCD \<60 mmHg, OCD \>120 mmHg, breath rate \>35, SpO2 \<90),
* Those who do not have secure unsupported sitting balance and have a score of \>3/5 (Oxford scale) in the lower limbs,
* Patients whose Richmond agitation sedation scale (RASS) is between +1 and +4 points, and patients with a score between -1 and -5,
* Those with arrhythmia,
* Patients without arterial monitoring,
* Patients whose FiO2 percentage is not 30% in patients on mechanical ventilator,
* Patients who do not have ventilation method (mod) PASB in patients on mechanical ventilator,
* Patients who do not have a PEEP value of 5 in patients on mechanical ventilators,
* Patients who do not have a PASB value of 10 in patients on mechanical ventilators,
* Those with neurological and orthopedic contraindications,
* Patients who could not get approval from the relatives of the patients who did not accept to participate in the study were excluded from the study.
Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia

Postoperative nausea and vomiting (PONV) is one of the most undesirable complications after general anesthesia, and may lead to increased hospital stay and health care costs. The risk factors for PONV include sex (female population), nonsmoking status, past history of motion sickness and/or previous PONV, duration of anesthesia and surgical type (particular gynecologic surgery) and postoperative use of opioids. The overall incidence of PONV has been reported to be 30% with considerable variability, but can increase up to 69%- 80% in women undergoing gynecologic surgery with general anesthesia and morphine-patient controlled analgesia (PCA). Serotonin receptor antagonists (5-HT3) have been suggested one of the first line therapies for preventing PONV because of their efficacy and few side effects compared with other antiemetics. However, despite the use of this treatment, the incidence of PONV has been reported to be between 48 % and 50%. Naloxone is a drug used to counter the effects of opioid. It was found that administration of low dose naloxone prevents opioid side effects such as nausea and pruritus without affecting analgesia or opioid requirements in patient receiving morphine PCA. It was reported that the use of two antiemetic acting at different mechanisms is better to prevent PONV than monotherapy.

Therefore, this prospective, randomized, controlled study was designed to investigate the antiemetic efficacy of combination of ramosetron and premixture of naloxone with morphine PCA after gynecologic surgery.


Eligibility Criteria:
Inclusion Criteria:

* Nonsmoking women (ASA physical status of I or II) scheduled for gynecologic surgery under general anesthesia and postoperative analgesia with a PCA device were included

Exclusion Criteria:

* known hypersensitivity to study medication; the use of antiemetics within 24 hours before surgery; the presence of gastrointestinal, renal, hepatic, or psychiatric disease.
A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine

The study is an open-label, randomized,2-period, single dose, crossover study in 8 healthy male/female volunteers. Subjects will be randomized to the following sequences:

(A) Period 1: KT110 - wash-out period - Period 2: Alpress and Periactin marketed tablets ; Or (B) Period 1: Alpress and Periactin marketed tablets - wash-out period - Period 2: KT110


Eligibility Criteria:
Inclusion Criteria:

* Healthy male/female subject
* Females of childbearing potential and male participant must agree to use an adequate and highly effective method of contraception
* Negative serum pregnancy test at screening for woman of childbearing potential only
* Non-smoker subject or smoker of not more than 5 cigarettes a day
* Body Mass Index (BMI) between 18.5 and 30 kg/m2 inclusive, at screening

Exclusion Criteria:

* Any contraindication to Prazosin or Cyproheptadine treatments;
* Frequent headaches and / or migraine, recurrent nausea and / or vomiting;
* Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease equal to or greater than 20 mmHg in systolic blood pressure (SBP) and a decrease equal to or greater than 10 mmHg in diastolic blood pressure (DBP) within two minutes of changing from supine to standing position;
* Blood donation (including as part of a clinical trial) in the 2 months before administration
* Any drug intake (except paracetamol or contraception) during the month prior to the first administration;
* History or presence of drug or alcohol abuse (alcohol consumption \> 40 grams / day)
* Excessive consumption of beverages with xanthine bases (\> 4 cups or glasses / day);
* Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests
* Positive results of screening for drugs of abuse